Category: Asean

Posted on

[INVNT GROUP]™ the Global Brand Storytelling Agency Portfolio, Expands to South Asia Opening Tenth Office in Mumbai, India

Mumbai, India, Jan. 10, 2024 (GLOBE NEWSWIRE) — [INVNT GROUP] The Global BrandStory Project™, announces its expansion into South Asia opening its tenth office across seven countries in Mumbai, India. The move aligns with the Group’s vertical and horizontal growth strategy, which supports the increasing demand for innovative brand storytelling in one of the fastest-growing markets including Tata Motors, Hitachi Vantara, Samsung, Amazon, Unilever, Sun Pharmaceutical, and more.

With a significant presence already established in key locations such as New York, London, Sydney, Singapore, Dubai, San Francisco, Detroit, Washington D.C, and Stockholm, the addition of Mumbai to [INVNT GROUP]’s global footprint marks another step in bolstering its services to both local and multinational clients.

“We are excited to extend our reach and expertise to South Asia, a region that is rapidly emerging as a hub for technological and marketing communications innovation. Establishing a base in Mumbai is not solely a strategic decision but also a response to our client’s growing needs to engage and build wider and deeper communities. It reinforces our commitment to delivering impactful brand stories globally and locally, catering to the unique challenges and opportunities in the region. Our goal is to create unparalleled brand experiences that resonate deeply with local audiences and set new standards in creativity and strategic execution on the global stage. We’re also thrilled to welcome Laveesh Pandey, who joins our team with the perfect experience to drive the group’s expansion in the region,” said Scott Cullather, President & CEO of [INVNT GROUP], and CEO of INVNT.ATOM.

Laveesh Pandey has been appointed Managing Director of [INVNT GROUP] South Asia, reporting into Scott Cullather and Kristina McCoobery, INVNT CEO and [INVNT GROUP], COO. Pandey, previously Chief Operating Officer at Starlight Gaming, joins the global agency with over two decades of experience in the Media & Entertainment industry. Having held key positions at MindShare, Reliance Entertainment, Zapak Digital Entertainment and Clockwork Events, Pandey brings a deep knowledge of technology, gaming, experiential marketing, and advertising, with his award-winning leadership powering transformative B2B and B2C brand experiences.

“I am elated to lead [INVNT GROUP]’s expansion into South Asia, particularly in the dynamic and crowded Indian market. Brands in this region are eager for innovative ways to stand out, and we are here to deliver a blend of global best practices with deep local insights. In a world that is rapidly evolving, our focus is on connecting brands with their most important communities and audiences in meaningful, authentic, and engaging ways. With [INVNT GROUP]’s diverse capabilities, we are set to redefine brand storytelling in the vibrant South Asian market, creating real impact through the next great era of brand engagement in this region,” said Laveesh Pandey, Managing Director of [INVNT GROUP] South Asia.

INVNT™ also welcomes Abhishek Pandey as Producer (previously Senior Manager of Operations & Client Relations at MidasNext Media), and Varun Parashar as Manager of Account Services (previously Marketing & Community Lead at Starlight Gaming).

With this expansion, [INVNT GROUP] continues to uphold its vision of engaging audiences everywhere by crafting compelling and impactful brand stories across all platforms.

For more information, please visit [INVNT GROUP].

###

ABOUT [INVNT GROUP]
[INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT™ is a growing portfolio of complementary disciplines designed to help forward-thinking organizations everywhere, impact the audiences that matter, anywhere, with offices in New York, London, Sydney, Singapore, Dubai, San Francisco, Mumbai, Stockholm, Detroit, and Washington D.C. Led by President and CEO, Scott Cullather, [INVNT GROUP]™ was established as a growing evolution of the live global brand storytelling agency INVNT™, with a vision to provide engaging, well-articulated, impactful brand stories across all platforms.

The GROUP consists of: modern brand strategy firm, Folk Hero™; creative-led culture consultancy, Meaning; production studio & creative agency, HEVĒ™; events for colleges and universities, INVNT Higher Ed; digital innovation division, INVNT.ATOM™; creative multimedia experience studio, Hypnogram™; ITP Live (Any Venue Video, Thunder Audio, In Sync), portfolio of full-service production for live entertainment; and the original live global brand storytelling agency, INVNT.

Attachment

Jhonathan Mendez de Leon
[INVNT GROUP]
Jmendezdeleon@invnt.com

GlobeNewswire Distribution ID 9015785

Posted on

[INVNT GROUP]™ the Global Brand Storytelling Agency Portfolio, Expands to South Asia Opening Tenth Office in Mumbai, India

Mumbai, India, Jan. 10, 2024 (GLOBE NEWSWIRE) — [INVNT GROUP] The Global BrandStory Project™, announces its expansion into South Asia opening its tenth office across seven countries in Mumbai, India. The move aligns with the Group’s vertical and horizontal growth strategy, which supports the increasing demand for innovative brand storytelling in one of the fastest-growing markets including Tata Motors, Hitachi Vantara, Samsung, Amazon, Unilever, Sun Pharmaceutical, and more.

With a significant presence already established in key locations such as New York, London, Sydney, Singapore, Dubai, San Francisco, Detroit, Washington D.C, and Stockholm, the addition of Mumbai to [INVNT GROUP]’s global footprint marks another step in bolstering its services to both local and multinational clients.

“We are excited to extend our reach and expertise to South Asia, a region that is rapidly emerging as a hub for technological and marketing communications innovation. Establishing a base in Mumbai is not solely a strategic decision but also a response to our client’s growing needs to engage and build wider and deeper communities. It reinforces our commitment to delivering impactful brand stories globally and locally, catering to the unique challenges and opportunities in the region. Our goal is to create unparalleled brand experiences that resonate deeply with local audiences and set new standards in creativity and strategic execution on the global stage. We’re also thrilled to welcome Laveesh Pandey, who joins our team with the perfect experience to drive the group’s expansion in the region,” said Scott Cullather, President & CEO of [INVNT GROUP], and CEO of INVNT.ATOM.

Laveesh Pandey has been appointed Managing Director of [INVNT GROUP] South Asia, reporting into Scott Cullather and Kristina McCoobery, INVNT CEO and [INVNT GROUP], COO. Pandey, previously Chief Operating Officer at Starlight Gaming, joins the global agency with over two decades of experience in the Media & Entertainment industry. Having held key positions at MindShare, Reliance Entertainment, Zapak Digital Entertainment and Clockwork Events, Pandey brings a deep knowledge of technology, gaming, experiential marketing, and advertising, with his award-winning leadership powering transformative B2B and B2C brand experiences.

“I am elated to lead [INVNT GROUP]’s expansion into South Asia, particularly in the dynamic and crowded Indian market. Brands in this region are eager for innovative ways to stand out, and we are here to deliver a blend of global best practices with deep local insights. In a world that is rapidly evolving, our focus is on connecting brands with their most important communities and audiences in meaningful, authentic, and engaging ways. With [INVNT GROUP]’s diverse capabilities, we are set to redefine brand storytelling in the vibrant South Asian market, creating real impact through the next great era of brand engagement in this region,” said Laveesh Pandey, Managing Director of [INVNT GROUP] South Asia.

INVNT™ also welcomes Abhishek Pandey as Producer (previously Senior Manager of Operations & Client Relations at MidasNext Media), and Varun Parashar as Manager of Account Services (previously Marketing & Community Lead at Starlight Gaming).

With this expansion, [INVNT GROUP] continues to uphold its vision of engaging audiences everywhere by crafting compelling and impactful brand stories across all platforms.

For more information, please visit [INVNT GROUP].

###

ABOUT [INVNT GROUP]
[INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT™ is a growing portfolio of complementary disciplines designed to help forward-thinking organizations everywhere, impact the audiences that matter, anywhere, with offices in New York, London, Sydney, Singapore, Dubai, San Francisco, Mumbai, Stockholm, Detroit, and Washington D.C. Led by President and CEO, Scott Cullather, [INVNT GROUP]™ was established as a growing evolution of the live global brand storytelling agency INVNT™, with a vision to provide engaging, well-articulated, impactful brand stories across all platforms.

The GROUP consists of: modern brand strategy firm, Folk Hero™; creative-led culture consultancy, Meaning; production studio & creative agency, HEVĒ™; events for colleges and universities, INVNT Higher Ed; digital innovation division, INVNT.ATOM™; creative multimedia experience studio, Hypnogram™; ITP Live (Any Venue Video, Thunder Audio, In Sync), portfolio of full-service production for live entertainment; and the original live global brand storytelling agency, INVNT.

Attachment

Jhonathan Mendez de Leon
[INVNT GROUP]
Jmendezdeleon@invnt.com

GlobeNewswire Distribution ID 9015785

Posted on

Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline Patient and Site Clinical Trial Experience

Companies partner to provide patients and sites with easy access to study information in one integrated solution

DURHAM, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, and Advarra, a leading provider of clinical research technology for clinical research investigator sites and sponsors, to deliver an integrated patient- and site-centric solution that streamlines the clinical trial experience.

In an industry faced with complex challenges to clinical trial execution, Fortrea is establishing an alliance of industry partners—beginning with founding members, Veeva and Advarra—to tackle some of these challenges head-on. Many sites are burdened by administrative operations that have multiple, complex technologies with limited interoperability. This impacts their ability to focus on what matters most—the patients—and improving their recruitment and experience participating in clinical studies.

Fortrea, Veeva and Advarra are partnering to offer a seamless, unified technology solution that integrates best-in-class technologies and leverages Fortrea’s process expertise. This will help ease the administrative burden for patients and sites and increase the accessibility of clinical trials for the public.

“We heard from our Site Advisory Board that the multitude of technologies used on a study is one of their greatest challenges,” said Fortrea Chief Operating Officer and President of Clinical Services Mark Morais. “Working with industry-leading partners and founding members, Veeva and Advarra, we’re taking action to remove complexities so we can address the pain points of sites and patients and make a difference. We are leveraging our unique vantage point in the industry that enables us to layer our expertise over the tech and data ecosystems from best-in-class partners—adding to our alliance as we go—to dramatically simplify the experience for patients, sites and sponsors.”

For sites, the partnership is set to deliver:

  • a cloud-based, simplified sign-on experience for Fortrea-run studies
  • access to study technologies through a single dashboard
  • a unified environment with a single repository for study documents and records

For patients, the solution is being designed to offer:

  • easy-to-access, step-by-step, visit-by-visit support and education throughout a patient’s trial journey
  • a simplified user experience through a single platform
  • self-referral functionality to search and find studies in their disease area of interest
  • ongoing patient support and education via an online portal or mobile app
  • a simplified mobile and web application for consenting and responding to outcome surveys

“Veeva is helping to advance clinical trials with connected applications that reduce the burden of participating for patients, streamline execution for research sites and increase transparency for sponsors,” said Jim Reilly, vice president, Veeva Development Cloud Strategy. “Extending our partnership with Fortrea to deliver Veeva Clinical Platform applications will meet the unique needs of patients, sites and sponsors while significantly improving study data quality and collaboration with sites.”

“Advarra’s mission is to break the silos that impede clinical research, so we are excited to provide our Longboat solution and IRB services as part of this innovative and collaborative partnership aimed at reducing site and patient burden,” said Elisa Cascade, chief product officer at Advarra.  “By leveraging our Longboat solution, Fortrea will deliver a reimagined clinical research experience that will improve both protocol compliance and site and patient engagement throughout the clinical trial process.”

Learn more about how Fortrea is driving healthcare innovation throughout the world at Fortrea.com. For more information on the technology platforms, visit Veeva Clinical Platform and Advarra Longboat.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9015283

Posted on

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.

Preliminary, Unaudited Fourth Quarter and Full Year 2023 Results

  • Revenue for the fourth quarter of 2023 is anticipated to be approximately €1.8 million, a 40% increase over the fourth quarter of 2022 and an 87% increase over the third quarter of 2023.
  • Revenue for the full year 2023 is anticipated to be approximately €4.3 million, a 41% increase over the full year 2022.
  • Ended the year with 48 active German accounts.

“We are excited with the strong preliminary fourth quarter sales, which are anticipated to be nearly double from last quarter. This anticipated growth reflects both strong underlying demand for Genio and focus on streamlining the patient referral pathway through initiatives such as our direct-to-consumer online campaigns launched in March,” commented Olivier Taelman, Chief Executive Officer. “This performance throughout 2023 sets the stage for an exciting 2024, as in a few months we expect to report data from our DREAM US pivotal trial, file for FDA approval, begin preparations to enter the US market, and begin to see contribution from the ResMed commercial partnership in Germany.”

The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until Nyxoah reports its full financial results for 2023 in its Annual Report on Form 20-F.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM US pivotal trial; filing for FDA approval; entrance to the US market, contributions from the ResMed commercial partnership in Germany; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000908020

Posted on

Institutional Investors’ Enthusiasm Grows for Innovative Private Equity Fund

Investors with deep pockets seek refuge in GDP Capital’s PE-BOND Fund amidst turbulent markets

Key Investment Sectors

Private Equity and other investment sectors are operatingin challenging and unpredictable environments today

KUALA LUMPUR, Malaysia, Jan. 09, 2024 (GLOBE NEWSWIRE) — The COVID-19 pandemic has unleashed unprecedented economic turmoil, resulting in contracting markets and dwindling returns worldwide.

Private Equity and other investment sectors find themselves navigating an exceptionally challenging and unpredictable landscape. In an environment with limited profitable opportunities, preserving dry powder appears to be a prudent choice. An alternative, however, has emerged—a haven for investors with substantial resources.

Private Equity and other investment sectors are operatingin challenging and unpredictable environments today

Private Equity and other investment sectors are operating
in challenging and unpredictable environments today

Introducing GDP Capital’s PE-BOND Fund LP, one of Private Equity’s latest offerings poised to make waves on the international stage. In today’s dismal or negative return environment, this fund has the potential to significantly enhance your return on investment while offering a sense of security.

GDP Capital’s investment structure is nothing short of unique, possibly the first of its kind. Here’s why it stands out:

  • A Private Equity structure fortified with the security of a bond.
  • Investments are channelled into government-approved projects.
  • Capital invested is backed by government guarantees and repaid within a 10-year horizon.
  • GDP Capital secures equity in the involved companies and their respective projects, each contributing dividend.

The Fund mandates a minimum commitment above US$25 million, making it ideally suited for Sovereign Wealth Funds, Retirement Funds, Institutional Investors, Endowments, Insurance Companies, Banks, Family Offices, and major investment firms.

A Balance of High Returns and Capital Safety:

“While structuring the fund, we overcame numerous hurdles to satisfy governmental, legal, regulatory, and investor requirements. After two years of meticulous development, potential investors are displaying keen interest,” commented Gurmit S. Sidhu, the founder and Managing Director of GDP Capital Limited, on the fund and its offerings.

With an adept team comprising tax and legal advisors, investment bankers, and political analysts, GDP Capital Limited stands ready to support top-tier investors in surpassing their investment objectives.

This unique investment Fund, set to launch in January 2024, is spearheaded by GDP Capital Limited, a Private Equity Fund Manager incorporated in the British Virgin Islands (BVI) and regulated by the BVI Financial Services Commission (BVI FSC).

GDP PE-BOND Fund LP represents an extraordinary opportunity for investors seeking capital safety and accelerated returns.

Explore the Merits Further:

Astute investors who recognize the benefits offered by GDP Capital may wish to delve deeper into its merits. For additional details, please visit: www.gdpcapitalltd.com

About GDP Capital Limited:

GDP Capital Limited is a Private Equity Fund Manager incorporated in the British Virgin Islands (BVI) and regulated by the BVI Financial Services Commission (BVI FSC). The firm collaborates with stable and investor-friendly governments seeking funding for priority projects to expedite economic development and achieve real GDP growth.

Funding is extended for viable and strategically significant government projects contributing to sustainable economic growth. While initially focusing on Asia, the company has expansion plans for other global regions. Given the substantial funding requirements of governments, GDP Capital provides institutional investors with the assurance of government guarantees, facilitating investments ranging from US$100 million to US$1 billion.

Media Contact:
Investor Relations
pr@gdpcapitalltd.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2a9a601f-7cd5-459c-b4f7-f42d96113ccd

GlobeNewswire Distribution ID 9014950

Posted on

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.

“Since initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease biology,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “We are excited to bring this asset into our internal pipeline and accelerate the compelling science behind this program while our research collaboration with Bayer focuses on precision oncology.”

Recursion applied phenotypic screening of human cells to identify small molecules that reverse the phenotypic features of disease-state fibrocyte cells into those of healthy-state cells. Leveraging the power of Recursion’s Maps of Biology and Chemistry revealed a relationship between small molecule hits and a novel target that could impact fibrotic diseases. The most promising small molecule hits were confirmed as potent inhibitors of this novel target in validation experiments, and lead optimization studies are currently ongoing.

Fibrotic diseases are a significant cause of morbidity and mortality worldwide with high unmet need for patients. One of the biggest challenges in the treatment of fibrotic diseases is the underlying complex biology and the associated difficulty in discovering disease-modifying drug targets. Recursion’s technology is uniquely suited to accelerate discoveries in these and other complex areas of disease biology.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9012419